|
|
|
|
|
|
Hello Cell & Gene readers, I'm happy to bring you April's most-clicked articles. Enjoy! Erin Harris, editor-in-chief
Follow me on X |
|
|
APRIL'S BEST FEATURED EDITORIAL |
|
|
Why A Cell Therapy CEO Waited Until Phase III To Outsource | By Louis Garguilo, chief editor, Outsourced Pharma | Sometimes, you have to go it alone. For a while, at least. Biotech has widely followed the mantra: engage your CDMO early, and let those experts guide you into manufacturing. Matthieu de Kalbermatten, CEO of CellProthera, a regenerative cell-therapy developer, begs to differ. |
|
|
|
|
APRIL'S BEST INDUSTRY INSIGHTS |
|
|
|
How AI Supports Data Recording And Quality | By CHDR | AI speeds early‑phase development by streamlining data review, enabling structured queries, accelerating PK/PD work, and revealing biomarker patterns — boosting efficiency with expert oversight. |
|
|
Advanced Technology Platform For Stem Cell-Derived Exosomes | By Elie Zakhem, Jae Jung, Cameron Garland, et al., Repligen | Demand for EVs is rising due to their therapeutic promise. Explore two scalable platforms that address production challenges to support EVs' expanding clinical and commercial applications. |
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
